Further phenotypic changes occurred during this IL-2/Jes6-1 treatment, namely an expanded population of IL-5+ ILC2 (Lin− ICOS+), associated eosinophilia and decreased CD11b+ Ly6G− Ly6Chi inflammatory monocytes (Supplementary Fig. 3A). The gene discussed is IL5; the disease is Increased total eosinophil count.